the inven2 start-up portfolio inven2.pdf · ndm-1 superbug. • preclinical phase • soft funding...
TRANSCRIPT
The Inven2 start-up portfolio
Nordic-American Life Science Conference 2018
Ole Kristian Hjelstuen, CEO
Disclaimer
• This presentation may contain certain forward-looking statements and forecasts based on best current knowledge. No assurance can be given that expectations arising from this presentation will prove to have been correct. Inven2 disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Inven2 is the Tech Transfer Office for
• The University of Oslo
• Oslo University Hospital, including the National Cancer Hospital
• All hospitals in South Eastern Norway, serving 50% of the Norwegian population
From Science to Business in Norway
Inven2 has, alone or jointly, started companies like
Nordic Nanovector
• Pharmaceutical company
• Listed on the Norwegian Stock Exchange main list
• Haematological cancers
• Betalutin – Non-Hodgkin’s Lymphoma – Phase II
CD37: the treatment target for Betalutin®
Antibody-177Lu conjugate
Figure from www.nordicnanovector.com
Vaccibody
• Tailored vaccine therapy
• Targeting Antigen Presenting Cells
• Phase I/IIa – HPV16-vaccine to treat precancerous cervical lesions
Figure from www.vaccibody.com
Ultimovacs
• Pharmaceutical company
• Pre-IPO
• UV1 – peptide based product
• Targeting telomerase (hTert)
• Phase I/IIa Cancer Therapeutic
• Ongoing studies in Lung, Prostate and Melanoma
Epiguard
• Medtech company • Patient isolation unit – patent pending • Established 2015 • Approved device – on the market in Europe – pending FDA approval • Pre-IPO
Our start-up portfolio
Status
Inven2 has established 82 companies
–15 exits
–45 active companies
–22 companies closed
Excellence in idea selection process
Idea selection
Company establishment
Verification, Project development
New start-ups
Cancer treatment using T-cells equipped with targeting units – CARs or TCRs – that seek out and kill cancer cells independently of their location in the patient
Preclinical phase to first patient
Adoptive T-Cell Therapy of Cancer
CAR: Chimeric Antigen Receptor TCR: T-Cell Receptor
Serca Pharmaceuticals Novel therapy for ischemic reperfusion injury
• Est Nov 2018
• US patent granted
• EU & J pat pending
• Radspherin® - 224Ra-microparticles • Peritoneal carcinomatosis • GMP Production labs complete • Product ready for phase I/II
Knut Erik Hovda
OUS
Gaut Gadeholt
OUS
Dag Jacobsen
OUS
Åsmund R. Kjendseth
NMBU
Orphan Diagnostics
MeTOX – Point-of-care methanol poisoning test. Validated for use
- 1 drop of blood – read-out after 3 minutes
- Single use product
- Simple to use
- Low production costs
Project pipeline
most advanced projects
PDE2 inhibition as a new therapeutic strategy for ventricular arrhythmias
• Novel mechanism of action for prevention of arrhythmias, likely to provide higher selectivity and fewer safety issues than current options
• Proof of concept demonstrated in two separate mouse models of disease, with two different PDE inhibitors
• Securing soft funding for 2019, possible start-up mid 2019
Lethal cardiac arrhythmia with control treatment
Normal heart rhythm with PDE inhibitor
Antibiotic complement drug against multi-resistance
• ZinChel, complement to beta-lactam antibiotics
• Lead cmpd ZN148 is only drug acting on resistance mechanism metallobetalactamase NDM, VIM, IMP
• ZN148 works on «New Dehli – bacteria» - the NDM-1 superbug.
• Preclinical phase • Soft funding one more yr • Collaboration project,
several universities
Normal self Peptide (CD20p)
Patient HLA
Normal self peptide (CD20p)
Patient HLA
Immunooncology: TCR factory
Lead product: A CD20-targeted T-cell receptor (TCR) for treatment of B-cell lymphoma
Competitiveness: Identification of high-potency TCRs from donor T cells (patented method)
Donor TCR Patient TCR
Patient B cell
Donor T cell Patent application: WO 2015/071763A2
Kumari et al, PNAS 2014, Stronen et al, Science 2016
Patient T cell
70 ongoing projects
• We are looking for investors who wants to enter the company initiation phase
• Visit www.inven2.com
• contact me on [email protected]
• +47 90824724
@inven2as